GLP-1 trial failure signals new multi-pathway approach to Alzheimer’s treatment

Daijiworld Media Network - London

London, Dec 13: Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show cognitive benefits, but experts say the outcome highlights a significant shift in how the brain-wasting disorder is being approached — moving away from single-target therapies towards a complex, multi-pathway strategy, similar to advances seen in cancer treatment.

At present, only two drugs — Eli Lilly’s Kisunla and Leqembi, developed by Eisai and Biogen — are approved to slow Alzheimer’s progression. Both target toxic amyloid plaques in the brain and have shown about a 30 per cent delay in disease progression. However, scientists are increasingly recognising that amyloid alone may not fully explain the disease.

Gl